We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Port Erin | PEBI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.50 |
| Top Posts |
|---|
Posted at 31/5/2019 12:39 by jimbob17 Notsure we have an ANIC thread yet but these are excellent heavyweight appointments I reckon :Agronomics Limited ("Agronomics" or the "Company") Board Appointments The Board of Agronomics, the AIM quoted company investing in the Life Sciences sector with a concentration on environmentally friendly alternatives to the traditional production of meat and plant-based nutrition sources, is pleased to announce the appointment of Richard Reed and David Giampaolo as Independent Non-Executive Directors to the Board with immediate effect. Richard Reed is also appointed as Non-Executive Chairman in succession to Jim Mellon who will remain on the Board as a Non-Executive Director. Denham Eke, Director comments: "I am delighted to welcome both Richard Reed and David Giampaolo to Agronomics as Independent Non-Executive Directors, and to welcome Richard Reed as Non-Executive Chairman of the Board. Richard's extensive experience, initially within Innocent Drinks and latterly as a venture capitalist, makes him the ideal candidate to take on this role. I am confident that under his stewardship the Company will deliver shareholder value as we transition from biopharma into an investing company with a clear focus on alternative food technology. David not only has an extremely successful background in health and fitness, but also as an entrepreneur with extensive connections which makes him a significant addition to our Board." Richard Reed, incoming Non-Executive Chairman, commented: "I am really pleased to have joined Agronomics as your new Chairman. I fully appreciate the importance for growth companies to clearly communicate the investment story not only to the current investor base but also to future investors who will support the development of the Company. There are many exciting prospects ahead for us and, as Chairman, I intend to work closely with the Board to help deliver shareholder value by securing the Company's position in providing access to opportunities in the alternative food sector." Richard Reed Richard Reed, CBE is a businessman, investor and entrepreneur. He is the co-founder of Innocent Drinks, an international company producing fresh fruit smoothies and vegetable pots sold in various outlets around the world, the majority of which was sold to Coca-Cola for more than US$ 500 million. Richard is also a co-founder and partner of JamJar Investments, a venture capital investment fund based in London UK, specialising in early stage, high growth consumer technology and offline companies. Richard is an alumnus of St John's College, Cambridge. At the 2016 Queen's Birthday Honours, Richard was appointed a Commander of the Order of the British Empire for services to the food industry and to charity. David Giampaolo David Giampaolo is a major shareholder and chief executive of Pi Capital, a London-based investor club. He is also a noted entrepreneur in the global health and fitness sector. David previously founded, built up and sold several businesses and health club chains in the US and Europe. He has been involved as an investor, advisor and board member of some of the largest and most successful health and fitness companies in the world including Fitness First, 24 Hour Fitness, Zumba Fitness and SARVA, India's largest chain of yoga and mindfulness studios. David is also Chairman of SCA Investments Limited, the parent company of Gousto, a recipe box company, using technology to provide extensive choice and personalization in an eco-friendly way. Full disclosure as required by AIM Rule 17 on Richard Reed and David Giampaolo is set out at the end of this announcement. |
Posted at 20/7/2018 11:55 by tomboyb My personal opinion and certainly that of other stocks is that investors by far prefer larger investment stakes in investee companies so any real upside if reflected in the share price of its own entity -Lets hope Mellon gets this one moving - |
Posted at 26/3/2017 09:53 by snape Nobody on the PEBI stand at Master Investor yesterday. Shabby. |
Posted at 12/10/2016 16:00 by rivaldo Hi tightfist. Thx for the NAV info - the discount to say 10.64p NAV still looks too much at present imo, though it's natural there should be some discount.On a £1.95m m/cap I just like the "option" element that any one of a number of investments could cause a multibagger here, whilst retaining some form of security by being invested in a portfolio rather than singly in SUMM, or DBC or whatever. I certainly don't track JM's investee companies - AFAICS he seems to have an extremely, erm, "mixed" record as an investor/NED! |
Posted at 12/10/2016 09:01 by tightfist Hi Rivaldo,Some muted interest in PEBI this morning; no news on the elimination of the discount.....The reverse takeover of DBC by LIFE is most welcome. I chatted with DBC at the Investor show a couple of years ago; their product struck me as a sure-fire winner on first acquaintance, but with no pre-IPO investment opportunity. We will see some numbers soon but I anticipate a substantial valuation uplift to the £95k seed funding in due course.I wasn't previously aware of LIFE; as a strategy do you track companies where JM is an NED, etc? LIFE seems to have been valued at cash two weeks ago and made it clear that an acquisition was imminent - seems like it was a good entry point?Cheers, tightfist |
Posted at 17/7/2013 12:18 by rivaldo This PEBI thread is partly due to its stake in Ampliphi Biosciences (APHB), in which I have a holding. The APHB thread is here:PEBI's m/cap with 23.2m shares in issue is exactly £1.9m at 8.25p (the ADVFN figure is wrong). NAV per share at 30/9/16 was 9.96p per share. As at around 23/11/16 a contributor to this thread has calculated it has increased to around 12.2p. Investments as at 30 June 2016 Value % of Total Portfolio Magna Biopharma Income Fund £1,312,807 56.4% Regent Pacific Group £302,568 12.9% Summit Corporation £197,513 8.5% Other quoted holdings £114,716 4.9% Other unquoted holdings £401,964 17.3% Total £2,329,568 100.0% As at 23/11/16, Regent Pacific has doubled since 30/6/16 (an increase of £300k), SUMM is up 50% (increase of £100k) and Magna is down around 8% (say £100,000 down). Plus, in late'15 PEBI invested £95k in the Diabetic Boot Company. This recent RNS from LIFE (shares currently suspended) indicated that DBC will be reversing into that company and floating on AIM: I'd imagine that the new valuation will be substantially above cost. Quote for Magna Biopharma Fund: |
Posted at 02/1/2013 16:49 by lagosboy TW holds some stock in Port Erin from his Rivington days - presumably he disclosed that.Without being specific to TW in any way,in my view tipsters are a complete waste of time and easiest way to lose money for the lazy investor.... what they are good at is sales and marketing. Why bother being a tipster if you are such a savvy investor ? This stock is undervalued on a sum of the parts valuation, but value depends entirely upon Jim Mellon's stock selection (it mirrors his personal hioldings) and he is clearly in the know and in the right space. You either back him or better putting your money elsewhere. It is illiquid and it will rely on liquidity events for major price movements. |
Posted at 16/9/2011 15:48 by outsizeclothes.com Saw this fall today to roughly cash value, and decided to take a small punt on 50k @ 8.75p.The main reason is that I heard his talk in Master Investor, which was pretty inspirational. But I'm not expecting anything much to happen, apart from initial purchases, for 3+ years. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
